articleTop 1% cited
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · Vol. 32(10) · pp. 1020–1030
Suzanne L. Topalian✉Mario SznolDavid F. McDermottHarriet M. KlugerRichard D. CarvajalWilliam H. SharfmanJulie R. BrahmerDonald P. LawrenceMichael B. Atkins(Georgetown University)John D. PowderlyPhilip D. LemingEvan J. LipsonIgor PuzanovDavid C. SmithJanis M. TaubeJon M. Wigginton(Bristol-Myers Squibb (Germany))Georgia Kollia(Bristol-Myers Squibb (Germany))Ashok Gupta(Bristol-Myers Squibb (Germany))Drew M. PardollJeffrey A. SosmanF. Stephen Hodi
Abstract
Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations. Responses were durable and persisted after drug discontinuation. Long-term safety was acceptable. Ongoing randomized clinical trials will further assess the impact of nivolumab therapy on overall survival in patients with metastatic melanoma.
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune ResponsesMedicineNivolumabDiscontinuationInternal medicineMelanomaRefractory (planetary science)OncologySurvival analysisToxicityProportional hazards model
MeSH terms
NivolumabAdultAntibodies, MonoclonalAntineoplastic AgentsFemaleHumansMaleMelanomaMiddle AgedSkin NeoplasmsSurvival RateDisease-Free SurvivalKaplan-Meier Estimate
Funding
- Massachusetts General Hospital
Citations
2,198
FWCI
143.77
field-weighted impact
References
41
Percentile
100%
vs. same field & year
Citations per year
Cited by
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Oncotarget · 2015 · 322 citations
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Science Translational Medicine · 2016 · 2,413 citations
The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
Frontiers in Pharmacology · 2014 · 385 citations
Immune Checkpoint Blockade in Cancer Therapy
Journal of Clinical Oncology · 2015 · 2,706 citations
Classifying Cancers Based on T-cell Infiltration and PD-L1
Cancer Research · 2015 · 1,441 citations
PD-1 and its ligands are important immune checkpoints in cancer
Oncotarget · 2016 · 321 citations
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Clinical Cancer Research · 2015 · 865 citations
References
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine · 2002 · 4,970 citations
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Science Translational Medicine · 2012 · 2,123 citations
The blockade of immune checkpoints in cancer immunotherapy
Nature reviews. Cancer · 2012 · 13,550 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research · 2009 · 3,204 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine · 2012 · 7,941 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.